Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.
| Original language | English |
|---|---|
| Pages (from-to) | 2539-2545 |
| Number of pages | 7 |
| Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Volume | 40 |
| Issue number | 23 |
| DOIs | |
| Publication status | Published - 10 Aug 2022 |
Bibliographical note
Funding Information:Supported by NRG Oncology Operations grant U10CA180868, NRG Oncology SDMC grant U10CA180822, NCORP grant UG1CA189867, and the NRG Specimen Bank grant U24CA196067 from the National Cancer Institute (NCI). Further supported by a donation from the Kankerbestrijding/ KWF from the Netherlands through the EORTC Cancer Research Fund, by the EORTC Translational Research Fund Grant No. TRF 01/02, by AstraZeneca EORTC Translational Research Grant No. AZ/01/02, by the Dutch Cancer Society Grants DDHK 2005-3416 and EMC 2007-3932, by grants from Stichting StopHersentumoren.nl, the Dutch Foundation for Scientific Research ZonMw (95110051 and 92003560) Programme Translational Research (PTO). A.B.L. was supported in part by The William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian Hospital, The Michael Weiner Glioblastoma Research Into Treatment Fund, and NCI/NIH grants P30CA013696 and UG1CA189960.
Publisher Copyright:
© American Society of Clinical Oncology.
